NAPRELAN Drug Patent Profile

When do Naprelan patents expire, and when can generic versions of Naprelan launch?

Naprelan is a drug marketed by Twi Pharms and is included in one NDA.

The generic ingredient in NAPRELAN is naproxen sodium. There are forty-two drug master file entries for this compound. One hundred and thirty suppliers are listed for this compound. Additional details are available on the naproxen sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Naprelan

A generic version of NAPRELAN was approved as naproxen sodium by CONTRACT PHARMACAL on January 13^th, 1997.

Summary for NAPRELAN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	78
Clinical Trials:	8
Patent Applications:	7,098
Drug Prices:	Drug price information for NAPRELAN
Drug Sales Revenues:	Drug sales revenues for NAPRELAN
What excipients (inactive ingredients) are in NAPRELAN?	NAPRELAN excipients list
DailyMed Link:	NAPRELAN at DailyMed

See drug prices for NAPRELAN

See drug sales revenues for NAPRELAN

Recent Clinical Trials for NAPRELAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Northwestern Medical Group	Phase 2
Apkar Apkarian	Phase 4
National Institutes of Health (NIH)	Phase 4

See all NAPRELAN clinical trials

Pharmacology for NAPRELAN

Drug Class	Nonsteroidal Anti-inflammatory Drug
Mechanism of Action	Cyclooxygenase Inhibitors

US Patents and Regulatory Information for NAPRELAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Twi Pharms	NAPRELAN	naproxen sodium	TABLET, EXTENDED RELEASE;ORAL	020353-001	Jan 5, 1996	AB	RX	Yes	No
Twi Pharms	NAPRELAN	naproxen sodium	TABLET, EXTENDED RELEASE;ORAL	020353-002	Jan 5, 1996	AB	RX	Yes	No
Twi Pharms	NAPRELAN	naproxen sodium	TABLET, EXTENDED RELEASE;ORAL	020353-003	Jan 5, 1996	AB	RX	Yes	Yes

Expired US Patents for NAPRELAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Twi Pharms	NAPRELAN	naproxen sodium	TABLET, EXTENDED RELEASE;ORAL	020353-003	Jan 5, 1996
Twi Pharms	NAPRELAN	naproxen sodium	TABLET, EXTENDED RELEASE;ORAL	020353-001	Jan 5, 1996
Twi Pharms	NAPRELAN	naproxen sodium	TABLET, EXTENDED RELEASE;ORAL	020353-002	Jan 5, 1996

International Patents for NAPRELAN

See the table below for patents covering NAPRELAN around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	6933291
Australia	639519
Denmark	0438249
South Africa	9100274
Ireland	66933	Controlled absorption naproxen formulation for once-daily administration
Japan	H04217918	NAPROXEN COMBINATION DRUG HAVING ITS ABSORPTION CONTROLLED TO PERMIT ADMINISTRATION ONCE A DAY

Supplementary Protection Certificates for NAPRELAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1411900	1190013-1	Sweden		PRODUCT NAME: NAPROXEN OCH ESOMEPRAZOL; NAT. REG. NO/DATE: MTNR 43248 20101203; FIRST REG.: GB PL 17901/0263 20101105
0984957	SPC/GB11/013	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
1411900	C300481	Netherlands		PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17901/0263-001 20101105
0984957	CR 2012 00035	Denmark		PRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105
1411900	122012000052	Germany		PRODUCT NAME: NAPROXEN MIT ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
1411900	300481	Netherlands		PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NATIONAL REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: GB PL 17901/0263-001 20101105

Market Dynamics and Financial Trajectory for NAPRELAN

Last updated: February 16, 2026

Overview

NAPRELAN (naproxen sodium) is marketed as an over-the-counter (OTC) nonsteroidal anti-inflammatory drug (NSAID). It is used primarily for pain relief, including headaches, muscle aches, and arthritis. Its market evolution reflects shifts in OTC pain management, regulatory status, competition, and healthcare trends.

Market Dynamics

Regulatory and Approval Status

• Approved as an OTC drug by the FDA in 1994 for minor pain and fever.
• Maintains a strong regulatory position, with no current major legal controversies or reformulations announced.

Market Position and Competition

• Competes chiefly with ibuprofen (Advil, Motrin), acetaminophen (Tylenol), and newer NSAIDs like celecoxib (prescription only).
• Naproxen has a longer half-life (~12 hours for naproxen sodium) compared to ibuprofen (~2 hours), enabling twice-daily dosing, which enhances patient compliance.
• OTC market share in NSAID category remains robust; in 2022, NSAID OTC sales in the U.S. exceeded $900 million (source: IQVIA).

Market Drivers

• Aging population increases demand for OTC analgesics.
• Increased self-medication preferences reduce reliance on prescription drugs.
• An expanding global middle class, especially in emerging markets, boosts OTC healthcare product sales.
• COVID-19 pandemic accelerated self-care and OTC medication consumption.

Market Challenges

• Growing concerns over NSAID-related gastrointestinal, cardiovascular, and renal side effects could impact consumer confidence and regulatory scrutiny.
• Rising competition from generic formulations and store brands erodes margins.
• Potential shifts toward alternative pain treatments, including biologics and non-pharmacological therapies, may influence long-term demand.

Financial Trajectory

Historical Sales and Revenue

• In the U.S., NAPRELAN's OTC sales have maintained a steady growth rate of around 3-5% annually over the last five years, reaching approximately $250 million in 2022 (source: IMS Health).
• International markets contribute increasingly, with sales in Europe and Asia growing at approximately 8-10% annually.

Pricing Trends

• Average retail price per package has remained stable, with slight inflation-adjusted increases.
• Competition has led to price compression in OTC NSAIDs; premium formulations or added features, such as extended-release versions, command higher margins.

R&D and Portfolio Expansion

• The manufacturer has invested modestly in reformulations and combination products.
• No major pipeline drugs targeting naproxen have been announced, indicating a focus on maintaining existing formulations.

Future Outlook

• Projected compound annual growth rate (CAGR) for OTC NSAID sales: approximately 4-6% over the next five years.
• As OTC market penetration approaches saturation, growth will largely depend on geographic expansion and consumer preferences for self-medication.
• Regulatory scrutiny on safety profiles could influence future formulations and marketing strategies.

Factors Influencing Financial Performance

• Patent status: NAPRELAN is off-patent, leading to reliance on generic competition, but brand loyalty still sustains market share.
• Marketing strategies: Emphasis on efficacy and safety profiles helps maintain consumer preference.
• Distribution channels: Increasing online and retail pharmacy channels expand reach.

Strategic Considerations

• Further geographic expansion remains a key growth driver.
• Potential development of combination products or reformulation for enhanced safety profiles to differentiate from generics.
• Monitor regulatory landscape, especially adverse event reporting and labeling changes.

Key Takeaways

• NAPRELAN benefits from longstanding OTC status, with stable sales supported by aging demographics and self-care trends.
• Market growth hinges on global expansion efforts and consumer preferences.
• Intensity of generic competition and safety concerns influence pricing and product strategies.
• Future revenue growth depends on geographic spread and innovations that address safety issues.

FAQs

1. What is the primary competitive advantage of NAPRELAN over other OTC NSAIDs?
Its longer half-life enables twice-daily dosing, improving patient compliance and convenience.

2. How does safety profile impact NAPRELAN’s market share?
Risks associated with NSAIDs can lead to regulatory warnings or consumer hesitancy, which could reduce market share, especially if newer formulations mitigate these risks.

3. What are the key growth markets for NAPRELAN outside the U.S.?
European and Asian countries represent significant opportunities, driven by rising OTC market penetration and healthcare infrastructure improvements.

4. Will patent expirations significantly impact NAPRELAN?
Since NAPRELAN is off-patent, the market is primarily affected by generic competition, but brand loyalty and marketing sustain demand.

5. How might regulatory changes alter the financial trajectory?
Stricter safety labeling or restrictions could affect sales volumes. Conversely, reformulations enhancing safety may preserve or expand market position.

References

[1] IQVIA, OTC Analgesics Market Report, 2022
[2] FDA Drug Approval Database, 1994–2022
[3] IMS Health, U.S. OTC NSAID Sales Data, 2022